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ABSTRACT 
AIM: To describe use of dietary vitamin, mineral and herbal supplements before and during 
pregnancy. 
METHODS: Pregnant women attending antenatal care at two tertiary Sydney hospitals 
between January and March 2014 completed an anonymous survey. Information on general 
maternal and pregnancy characteristics and the use of dietary and herbal supplements, 
including type, duration, and sources of information was collected. Frequency and 
contingency tabulations were performed. 
RESULTS: 612 women agreed to participate (91% response rate). 23 were excluded due to 
incomplete data. Of 589 women included in the analysis, the mean gestational age at the time 
of survey was 28.5 weeks (SD 8.3), 55% had no children, and 67% were tertiary educated. 
Overall 62.9% of women reported taking a multivitamin (MV) and/or folic acid (FA) 
supplement in the 3 months pre-pregnancy. At the time of the survey 93.8% of women were 
taking at least one supplement (median 2, range 1-13). During pregnancy 79.1% of women 
were taking MVs, including 59.2% taking MV only and 19.9% taking MV and FA. The 5 
most common supplements outside of a MV were FA (31%), iron (30%), vitamin D (23%), 
calcium (13%) and fish oil (12%).  
CONCLUSION: Use of folic acid and MVs and other supplements during and pre-pregnancy 
is relatively high, although pre-pregnancy FA supplementation rates could still be improved.  
Further research on the actual dosages and dietary intakes consumed are needed to examine 
whether pregnant women have adequate intake of nutrients, regardless of supplement use. 
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INTRODUCTION 
Dietary supplement use is increasing worldwide, including among pregnant women.
1, 2
  It is 
well-known that a woman’s nutritional status before and during pregnancy influences the well-
being of both mother and fetus.
3
 Pregnant women aiming to optimise their own or their baby’s 
health may use dietary supplements.
4
 
 
Folic acid (FA) / folate supplement use is recommended pre and in early pregnancy to reduce 
the risk of fetal neural tube defects (NTD).
5
 In pregnant women without malnutrition, the 
necessity or benefit of other nutrients supplied via dietary supplements is unclear.
3
 A variety 
of dietary supplements are commercially available; some contain FA alone, while others 
contain single or multiple vitamins, minerals or herbal ingredients. Some studies have pointed 
out that the safety, or evidence base of dietary supplements containing herbal ingredients, is 
not conclusive for pregnancy.
6-9
  
 
There is limited information on dietary supplement use before and during pregnancy among 
women of all gestational ages. A survey of 588 women near term in Melbourne in 2004, found 
that 36% of women took at least one herbal supplement, the most common being raspberry 
leaf (14%), ginger (12%) and chamomile (11%).
10
 With increased availability and marketing, 
dietary supplement use in pregnant women is expected to increase in Australia. Therefore, the 
aim of this study was to examine the current status of dietary supplement use before and 
during pregnancy, and characteristics of pregnant women taking these. 
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MATERIALS AND METHODS 
A cross-sectional survey of pregnant women attending antenatal care between January and 
March 2014 was conducted at two tertiary teaching hospitals in Sydney, New South Wales: 
Royal North Shore Hospital and the Royal Hospital for Women. Eligibility criteria included 
the ability to complete the questionnaire in English. Women may have been attending medical 
and/or midwifery models of care, or shared-care with their general practitioner. Women were 
given verbal and written information about the study and consent was ascertained via the 
woman returning the completed survey to the recruiter or a covered marked box. 
 
The aim of the survey was to collect information about vitamin, mineral and herbal 
supplement use 3 months before pregnancy and during the current pregnancy. The survey was 
self-administered and anonymous, and took approximately 10 minutes to complete. No 
pregnancy outcomes were determined. The survey was developed based on a review of 
literature, existing surveys, and discussion with researchers and midwives. After piloting the 
survey, minor modifications were made in the sequence, but not to the content of questions. 
The survey consisted of 22 items organised into three sections. Section 1 collected information 
on general maternal and pregnancy characteristics such as age, education level, parity, 
gestational age, height and weight, intake of red meat and food allergies, restrictions and 
intolerances.  Section 2 collected information on previous pregnancy factors regarded as 
potential determinants of current iron status and/or iron supplement use. These factors and 
other survey data related to iron have been reported elsewhere (Chatterjee, unpublished). 
Section 3 collected data on type(s) of supplements consumed in the 3 months prior to the 
current pregnancy and during the current pregnancy.  Response options for type(s) of 
supplements 3 months prior to pregnancy included: none, multivitamin (MV), FA, iron and 
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Vitamins D, B and A, and ‘other’. Current MV supplement use was categorised as either yes 
or no, and the response options for the combination of vitamins, herbs or dietary supplements 
that women were currently taking, that were not in the form of a MV, comprised a list of 18 
items including: none, iron, FA, vitamin A, vitamin D, calcium, nettle leaf and ginseng.  
Women were asked to tick more than one response option, if applicable. Women were also 
asked about the average amount of money spent per month and main sources of information 
for dietary supplement use in pregnancy.    
 
Maternal age was categorised into <25, 25-34, and >35 years. Gestational age was categorised 
into ≤20, 21-26 and ≥27 weeks to correspond with gestational age distribution of responses 
and then dichotomised to <20 and ≥20 weeks taking into account that many women do not 
book for antenatal care until closer to 20 weeks gestation. Body mass index (BMI; kg/m
2
) was 
calculated using patient reported pregnancy booking weight and height, and categorised using 
international standards.
11
 Ethics approval was obtained for both sites (HREC# 
LNR/13/HAWKE/340). 
 
Statistical analysis 
Cross-tabulations were used to examine use of MVs and FA 3 months before pregnancy and 
during the current pregnancy, by gestational age at time of survey (<20 or ≥20 weeks) and by 
maternal and pregnancy characteristics. Descriptive statistics of the prevalence of dietary 
supplement use 3 months prior to, and during the current pregnancy, and pregnancy 
characteristics of respondents were estimated for MV and any type of dietary supplement. 
Current intake of individual dietary vitamin, mineral, and herbal supplements (outside MV 
supplement) was examined from highest to lowest prevalence and compared by mean (SD) 
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gestational week at the time of survey using the Satterthwaite statistic to test for statistically 
significance differences.  The most common individual dietary vitamin, mineral, and herbal 
supplements (FA, vitamin D, calcium, and fish oil) were compared by maternal and pregnancy 
characteristics.  Descriptive statistics involved percentage tabulation and contingency tables. 
Statistical testing was performed using Chi-squared (X
2
) test, or in the case of small cell sizes, 
the Fisher’s exact test for categorical variables and the Wilcoxon signed rank test for 
continuous variables. All analyses were performed using SAS version 9.3 (SAS Institute Inc) 
and P-values <0.05 were considered statistically significant.  
 
RESULTS 
Of 674 women invited to participate, 612 agreed to participate (91% response rate). After 
excluding 23 women with incomplete data, 589 women were included in the final analysis.  
Two thirds of women (64%) were over 26 weeks’ gestation (mean gestation (weeks) ± SD: 
28.5±8.3), 55% had no children, 28% were overweight or obese, and 67% were tertiary 
educated (Table 1).  
 
In the three months before pregnancy, 66.5% of women reported taking any dietary 
supplement. Overall, 62.9% of women stated that they took either a MV and/or FA three 
months pre-pregnancy: of these 25.7% of women took a MV only, 19.9% took FA only and 
17.3% of women took both FA and a MV (Figure 1).  Apart from MV and FA supplement use, 
the prevalence of specific supplement use before pregnancy was 10.1% for iron, 6.7% for 
iodine, 13.2% for vitamin D, 5.5% for B vitamins, 2.1% for vitamin A, and 15.2% ‘other.’ The 
‘other’ category included a range of responses; however, the most frequently reported were 
calcium and fish oil.  
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At the time of survey, 93.8% of women reported taking at least one supplement. The majority 
of women (90.2%) were taking MV and/or folic acid (Figure 1). Overall 79.2% of pregnant 
women reported currently taking a MV supplement (Table 1): 59.2% of women a MV only 
and 19.9% both MV and FA, while another 10.1% of women were taking FA supplement 
only. There were no significant differences in maternal or pregnancy characteristics in women 
currently using or not using MV supplements, except women taking a MV were more likely to 
report having gestational diabetes mellitus (P<0.004). Compared to women not currently 
taking a MV, current MV users were more likely to have taken any type of supplement three 
months prior to pregnancy (i.e. MV and/or other dietary supplement) (53.3% vs. 70.0%, 
P=0.006) or a MV supplement (15.8% vs. 50.6%, P<0.001) but not a FA only supplement 
(42.5% vs. 35.5%, P=0.16).  There was no association between women’s gestational age at the 
time of survey (<20 and ≥20 weeks gestation) and reported supplement use for MV only 
(58.4% vs. 59.2%), FA only (13.6% vs. 9.0%), both (20.0% vs. 20.1%) or neither (8.0% vs. 
11.7%), respectively (P=0.35).  
 
A list of individual dietary vitamin, mineral, and herbal supplements taken by women at the 
time of survey is reported from highest to lowest prevalence and by mean (SD) gestational 
week at time of survey in Table 2. The 5 most common individual supplements used in the 
current pregnancy were FA (31%), iron (30%), vitamin D (23%), calcium (13%) and fish oil 
(12%). The average number of supplements taken alone or in addition to a MV was 2 and 
ranged from 1-13.   
 
Maternal characteristics for the four most common supplements taken in pregnancy, apart 
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from iron are presented in Table 3. Women who were taking vitamin D in the current 
pregnancy were less likely to be ≤ 20 weeks gestation (P<0.01) or underweight (P<0.04), and 
more likely to have gestational diabetes (P<0.001). Women taking calcium or fish oil were 
more likely to state that they had a food allergy, intolerance or dietary restriction (P<0.005), 
and calcium users were more likely to have high blood pressure (P<0.003).  All other 
examined characteristics showed no statistically significant differences. 
 
Women reported spending a median amount of $30 (interquartile range: $22- $50) per month 
on vitamin and mineral supplements. The six most commonly reported sources of information 
on vitamins and supplements were a doctor (69.1%), midwife/nurse (35.8%), internet (30.2%), 
family/friend (19.4%) pharmacist (15.5%) and naturopath (9%).  
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DISCUSSION 
We found high rates of FA and/or MV use, with two out of three women taking FA or MVs 
pre-pregnancy, and four out five women taking MV during pregnancy. Women also reported 
high rates of other supplement use, both pre and during pregnancy.  
 
Just over a third of women (37.3%) took pre-pregnancy FA, which is higher than that reported 
in other Australian studies, which have reported rates of 30% in South Australia
12
, 23% in 
Sydney
13
, 29% in Melbourne
14
, and 27% in Wollongong.
15
 Rates of MV use in our study (43% 
pre- and 79.1% during pregnancy) were also generally higher than those reported in other 
Australian studies: 11% MV pre-pregnancy and 35% MV during pregnancy in Melbourne
14
, 
32% MV in the first trimester in the Gold Coast
16
, and 82% of women taking supplements 
during pregnancy in Wollongong.
15
  Our findings are encouraging given the well known 
positive benefits of FA supplementation pre and in early pregnancy in reducing the risk of 
fetal NTD. Pre-pregnancy FA supplementation has also been associated with decreased risk of 
spontaneous miscarriage
17
, and a reduction in small for gestational age infants.
18
 These 
findings suggest some adherence with recommendations by The Royal Australian and New 
Zealand College of Obstetricians and Gynaecologists (RANZCOG)
5
 and the Australian 
National Clinical Practice Guideline for Antenatal Care.
19
 However, findings also revealed 
one third (37.1%) of women were not taking FA nor a MV pre-pregnancy, and it is not known 
whether all women who were taking pre-pregnancy MV were taking a MV containing FA. To 
help overcome inadequate intake of FA, food fortification with FA was introduced into 
Australia in 2009 to reduce the potential burden of NTD. Further research to identify the 
barriers to pre-pregnancy FA supplementation, and ongoing education of reproductive aged 
women about the importance of pre-pregnancy FA is still required.  
11 
 
 
 
 
Differences in maternal characteristics of the study populations may partly explain these 
differences in rates of supplement use compared to other studies, with women in this study 
predominately tertiary educated, older, and attending hospitals in geographical areas of higher 
income.
20
 This is consistent with a study from Denmark which found that in women planning 
pregnancy, (62% of who were taking FA and or MVs), those who were older, non-smokers, 
non–drinkers, physically active and had higher education and income, were more likely to take 
FA or MVs pre-pregnancy.
21
 
 
Of those taking FA, our findings highlight that women continued to take this beyond the first 
trimester. A meta-analysis has found no association with FA supplementation during 
pregnancy and a reduction in a range of pregnancy outcomes including preterm birth and 
stillbirth/ neonatal deaths; although there was some improvement in mean infant birthweight.
22
 
The benefit of ongoing folic supplementation beyond the first trimester remains uncertain and 
further trials are currently underway evaluating continued FA supplementation throughout 
pregnancy.
23
  
 
Commonly reported supplements used outside of a MV were vitamin D, calcium, iron and fish 
oil. Although the RANZCOG recommends vitamin D supplements in women with proven 
vitamin D deficiency and encourages considering testing those women with risk factors for 
vitamin D deficiency,
5
 and an association between maternal vitamin D status and offspring 
birth weight and bone mass has been reported, there is limited evidence that routine vitamin D 
supplementation in pregnancy improves outcomes for either mother or infant.
24
 However, 
calcium supplementation (≥ 1 gram/day) in pregnancy has been found in a meta-analysis to be 
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associated with a significant reduction in the risk of pre-eclampsia, particularly for women 
with low calcium diets, as well as reducing preterm birth and the occurrence of the composite 
outcome 'maternal death or serious morbidity'.
25
 Women taking calcium in this study were 
more likely to report having high blood pressure, and hence may be more likely to benefit 
from calcium supplementation. However, the benefit of omega-3/ fish oil supplements is weak 
with a recent systematic review reporting no association between omega 3 dietary supplements 
in pregnancy and preterm delivery, decreased maternal depressive symptoms or infant 
neurodevelopmental outcomes.
26
  
 
This study found that women taking calcium and fish oil were more likely to have a food 
intolerance or restriction, and were presumably aiming to achieve the recommended daily 
intake for nutrients by supplementation. However, the dose of calcium in many commonly 
used pregnancy MVs is small (range 0-140mg), as it makes the tablets large. Therefore women 
taking MV may be falsely reassured they are taking a “complete supplement” when their 
intake may be still below the recommended daily intake. Women in our study reported doctors 
and midwives as their primary sources of information, however many women and their care 
providers may not be aware of the actual ingredients of specific MVs, nor the recommended 
daily intakes of vitamins and minerals in pregnancy.
27
  
 
In terms of herbal supplement use, women in this study reported relatively low rates compared 
to other studies.
7, 28, 29
 The reasons for this difference are not known, but may reflect the study 
population characteristics or women’s sources of information.  Previous studies have found 
women from English-speaking backgrounds were more likely to take herbal supplements
7
 or 
13 
 
 
 
use complementary alternative medicine.
28
  
 
The main strengths of the study include the high response rate in two different hospitals. 
However, this study may be limited by recall bias with women self-reporting their pre-
pregnancy supplement use at a mean gestation of 28 weeks. In addition, the actual doses of 
individual vitamin/ minerals from supplements and/or from diet, or in the case of Vitamin D, 
from sunlight, are not known. Another limitation was the lack of pregnancy outcome data. The 
study may also have limited generalisability because the women were predominantly tertiary 
educated, older, and completed the survey in English.  Nevertheless, this study provides 
important and current information about dietary vitamin, mineral and herbal supplement use 
prior and during pregnancy. 
 
In conclusion, reported rates of pre-pregnancy FA and/or MV use are encouraging; however 
pre and early pregnancy FA supplementation could still be improved. Further studies are 
required to determine the role of dietary supplementation in pregnancy, evaluating pregnancy 
outcomes, measuring other important factors such as costs, nutrient intakes and diet.  
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Table 1. Maternal and pregnancy characteristics by multivitamin supplement use in the current pregnancy.  
 
 
 
Maternal and pregnancy characteristics 
Entire Sample Multivitamin use in the current pregnancy^ 
 
N=589 
Yes 
N=457 (79.2%) 
No 
N=120 (20.8%) 
 
 
P-value n (%) n (%) n (%) 
Maternal age, years 
 <25 
 25-34 
 ≥35 
 
29 (4.9) 
345 (58.6) 
215 (36.5) 
 
22 (4.8) 
269 (58.9) 
166 (36.3) 
 
7 (5.8) 
70 (58.3) 
43 (35.8) 
 
0.90 
Singleton pregnancy 557 (94.9) 432 (95.0) 115 (95.8) 0.69 
Gestational age at time of survey, weeks 
 ≤ 20  
 21-26  
 ≥ 27 
 
128 (22.0) 
80 (13.8) 
373 (64.2) 
 
98 (21.8) 
64 (14.2) 
288 (64.0) 
 
27 (22.7) 
16 (13.5) 
76 (63.9) 
 
0.96 
No previous children 323 (54.9) 202 (44.3) 59 (49.2) 0.34 
BMI categories 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 
58 (10.7) 
335 (61.6) 
94 (17.3) 
57 (10.5) 
 
44 (10.5) 
262 (62.4) 
73 (17.4) 
41 (9.8) 
 
14 (12.4) 
66 (58.4) 
19 (16.8) 
14 (12.4) 
 
0.77 
Smoker 8 (1.4) * *  
Educational attainment 
 Less than up to year 12 
 Trade/apprenticeship/diploma 
 University undergraduate or higher 
 
47 (8.1) 
144 (24.9) 
388 (67.0) 
 
31 (6.9) 
107 (23.9) 
309 (69.1) 
 
13 (10.8) 
34 (28.3) 
73 (60.8) 
 
0.17 
Vegetarian (no lamb, pork, beef or chicken) 5 (0.9) * *  
Any food allergy, intolerance or dietary restriction† 85 (14.5) 72 (15.9) 12 (10.0) 0.11 
Gestational diabetes 83 (14.1) 73 (16.0) 7 (5.8) 0.004 
High blood pressure  24 (4.1) 18 (4.0) 6 (5.0) 0.61 
Thyroid problem 50 (8.5) 41 (9.0) 9 (7.5) 0.60 
^ n=12 multivitamin use not reported. †Milk, egg, soy, wheat, shellfish/fish, lamb, beef, pork, chicken, gluten or other. *numbers 
too low to report. 
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Table 2 
Prevalence of individual dietary vitamin, mineral, and herbal supplement use in the current 
pregnancy (separate from multivitamin supplement use) from highest to lowest and by mean 
(±standard deviation) gestational week at the time of survey. 
 
 N=589 Gestational age at time of survey 
Individual supplement n (%) Mean (±SD) (weeks) 
Folic acid 180 (30.6) 27.3 (8.6) 
Iron 179 (30.4) 31.4 (7.6) 
Vitamin D 135 (22.9) 29.6 (7.9) 
Calcium 76 (12.9) 29.3 (8.3) 
Fish oil 71 (12.1) 30.3 (8.1) 
Vitamin C 48 (8.2) 29.1 (8.2) 
B Vitamins 38 (6.5) 29.8 (7.8) 
Iodine 37 (6.3) 28.3 (8.6) 
Zinc 33 (5.6) 28.4 (8.8) 
Raspberry leaf 26 (4.4) 35.8 (4.3) 
Vitamin A 14 (2.3) 26.9 (9.5) 
Spirulina 9 (1.5) 27.8 (9.0) 
Evening Primrose 9 (1.5) 36.8 (4.6) 
Other† 3 (0.5) 31.3 (10.7) 
†Other includes: nettle leaf (n=2), St. John Wort (n=1), fenugreek (n=1) and ginseng (n=1).  
None of the women reporting using valerian. 
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Table 3 
Maternal and pregnancy characteristics for selected dietary vitamin, mineral and herbal supplement use in the current pregnancy. 
 
 
 
 
Maternal and pregnancy 
characteristics 
Folic acid Vitamin D Calcium Fish oil 
Yes 
N=180 
(30.6%) 
No 
N=409  
(69.4%) 
Yes 
N=135 
(22.9%) 
No 
N=454 
(77.1%) 
Yes 
N=76 
(12.9%) 
No 
N=513 
(87.1%) 
Yes 
N=71 
(12.1%) 
No 
N=518 
(88.0%) 
 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Maternal age, years 
<25 
25-34 
≥35 
 
6 (3.3) 
106 (58.9) 
68 (37.8) 
 
23 (5.6) 
239 (58.4) 
147 (35.9) 
 
4 (3.0) 
85 (63.0) 
46 (34.1) 
 
25 (5.5) 
260 (57.3) 
169 (37.2) 
 
2 (2.6) 
46 (60.5) 
28 (36.8) 
 
27 (5.3) 
299 (58.3) 
187 (36.5) 
 
4 (5.6) 
38 (53.5) 
29 (40.9) 
 
25 (4.8) 
307 (59.3) 
186 (35.9) 
Singleton pregnancy 170 (94.4) 387 (95.1) 126 (94.0) 431 (95.1) 72 (94.7) 485 (94.9) 69 (97.2) 488 (94.6) 
Gestational age at survey, weeks 
≤ 20  
21-26  
≥ 27 
 
44 (24.7) 
25 (14.0) 
109 (61.2) 
 
84 (20.8) 
55 (13.7) 
264 (65.5) 
 
17 (12.8) 
22 (16.5) 
94 (70.7) 
 
111 (24.8)* 
58 (13.0) 
279 (62.3) 
 
12 (15.8) 
10 (13.2) 
54 (71.1) 
 
116 (23.0) 
70 (13.9) 
319 (63.2) 
 
10 (14.3) 
9 (12.9) 
51 (72.9) 
 
118 (23.1) 
71 (13.9) 
322 (63.0) 
No previous children 74 (41.1) 191 (46.8) 54 (40.0) 211 (46.6) 34 (44.7) 231 (45.1) 29 (40.9) 236 (45.7) 
BMI categories 
Underweight 
Normal weight 
Overweight 
Obese 
 
18 (10.7) 
95 (56.2) 
34 (20.1) 
22 (13.0) 
 
40 (10.7) 
240 (64.0) 
60 (16.0) 
35 (9.3) 
 
10 (7.9) 
71 (55.9) 
25 (19.7) 
21 (16.5) 
 
48 (11.5)* 
264 (63.3) 
69 (16.6) 
36 (8.6) 
 
4 (5.5) 
41 (56.2) 
20 (27.4) 
8 (11.0) 
 
54 (11.5) 
294 (62.4) 
74 (15.7) 
49 (10.4) 
 
3 (4.5) 
44 (65.7) 
14 (20.9) 
6 (9.0) 
 
55 (11.5) 
291 (61.0) 
80 (16.8) 
51 (10.7) 
Smoker 3 (1.7) 5 (1.2) 2 (1.5) 6 (1.3) 1 (1.3) 7 (1.4) 0 (0.0) 8 (1.6) 
Educational attainment 
Less than up to year 12 
Trade/apprenticeship/diploma 
≥University undergraduate 
 
15 (8.5) 
52 (29.6) 
109 (61.9) 
 
32 (7.9) 
92 (22.8) 
279 (69.2) 
 
11 (8.2) 
29 (21.6) 
94 (70.2) 
 
36 (8.1) 
115 (25.8) 
294 (66.1) 
 
6 (8.0) 
19 (25.3) 
50 (66.7) 
 
41 (8.1) 
125 (24.8) 
338 (67.1) 
 
5 (7.0) 
11 (15.5) 
55 (77.5) 
 
42 (8.3) 
133 (26.2) 
333 (65.6) 
Vegetarian† 2 (1.1) 3 (0.7) 0 (0.0) 5 (1.1) 0 (0.0) 5 (1.0) 1 (1.4) 4 (0.8) 
Any food allergy, intolerance or 
dietary restriction
‡
 
 
28 (15.6) 
 
57 (14.0) 
 
22 (16.3) 
 
63 (14.0) 
 
19 (25.0) 
 
66 (12.9)* 
 
20 (28.2) 
 
65 (12.6)* 
Gestational diabetes 22 (12.3) 61 (15.0) 35 (25.9) 48 (10.6)* 11 (14.5) 72 (14.1) 8 (11.4) 75 (14.5) 
20 
 
 
 
High blood pressure  7 (3.9) 17 (4.2) 5 (3.7) 19 (4.2) 9 (11.8) 15 (2.9)* 0 (0.0) 24 (4.6) 
Thyroid problem 15 (8.4) 35 (8.6) 8 (5.9) 42 (9.3) 5 (6.6) 45 (8.8) 5 (7.1) 45 (8.7) 
†Vegetarian includes women who reported not eating lamb, pork, beef or chicken. 
‡Milk, egg, soy, wheat, shellfish/fish, lamb, beef, pork, chicken, gluten or other. 
* P-value<0.05 
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Figure legend 
Prevalence of multivitamin and/or folic acid supplement use three months before pregnancy and 
during current pregnancy 
22 
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Figure 1 
Prevalence of multivitamin and/or folic acid supplement use three months before and during 
current pregnancy 
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